DelveInsight releases report of in-depth background and trends of the diabetic macular edema
The report is titled, Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.
(Image credit: AdobeStock/Nim)
DelveInsight has released a report entitled, “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.″ This report is a detailed look at diabetic macular edema (DME) epidemiology, and market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.1
According to the press release1, the report offers comprehensive insights into the DME revenue trends, prevalence, and treatment landscape. It also explores statistics, examines the efficacy and development of emerging therapies, and discusses the landscape of DME clinical trials.
Highlights of the Diabetic Macular Edema Market Report:1
- The DME market size was valued ~USD 2.9 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
- In 2022, the market size for DME across the US, EU4, the UK, and Japan was approximately USD 2,911 million.
- The market size is projected to grow during the forecast period (2023–2034) due to the introduction of upcoming therapies. In 2022, the US held the largest market share, with an estimated size of approximately USD 1,745 million.
- Key Diabetic Macular Edema Companies: Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharmaceuticals, RemeGen Co., Ltd., Alimera Sciences, Curacle Co., Ltd., Faricimab: Genentech, Inc., and others
- Key Diabetic Macular Edema Therapies: OCS-01, THR-149, Ranibizumab, EXN407, IBE-814, EYP-1901, RC-28E, Aflibercept, Conbercept, CU06-1004, and others
- The Diabetic Macular Edema market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage DME pipeline products will significantly revolutionize the DME market dynamics.
- DelveInsight's analysis revealed that the total prevalent cases of DME in the 7MM reached 1,073,892 in 2022, with expectations of a significant compound annual growth rate (CAGR) throughout the study period.
- The US had the highest number of diagnosed prevalent cases of DME, estimated at approximately 483,251 in 2022, and is expected to see a significant increase at a compound annual growth rate (CAGR).
- The diagnosed prevalent cases of DME were classified into three age groups: 18-44 years, 45-64 years, and 75 years and older. In 2022, the age group of 45-64 years had the highest number of cases, totaling 209,740 in the US.
More information on this report is available from DelveInsight.
